• About Us
    • What We Do
    • Our Story
    • Meet Our Team
  • Products
    • COVID-19 Response
      • COVID-19 Home Test
      • QIAreach COVID
      • ellume·lab COVID Tests
      • Swab+Drop COVID Self-Swab Kit
    • Consumer Products
      • COVID-19 Home Test
      • Influenza Home Test
    • Professional Products
      • ellume·lab
      • Swab+Drop Self-Swab Kit
    • Global Public Health Solutions
      • COVID-19
      • Tuberculosis
      • Pandemic Influenza
  • Our Tech
  • News
    • Corporate Announcements
    • Media
  • Careers
    • Australia
    • United States
  • Contact
  • About Us
    • What We Do
    • Our Story
    • Meet Our Team
  • Products
    • COVID-19 Response
      • COVID-19 Home Test
      • QIAreach COVID
      • ellume·lab COVID Tests
      • Swab+Drop COVID Self-Swab Kit
    • Consumer Products
      • COVID-19 Home Test
      • Influenza Home Test
    • Professional Products
      • ellume·lab
      • Swab+Drop Self-Swab Kit
    • Global Public Health Solutions
      • COVID-19
      • Tuberculosis
      • Pandemic Influenza
  • Our Tech
  • News
    • Corporate Announcements
    • Media
  • Careers
    • Australia
    • United States
  • Contact
QIAGEN receives U.S. FDA emergency use authorization for rapid portable SARS-CoV-2 antigen test

QIAGEN receives U.S. FDA emergency use authorization for rapid portable SARS-CoV-2 antigen test

August 6, 2021 Approval gives U.S. healthcare professionals access to a new combination of scalability and speed. QIAreach SARS-CoV-2 Antigen Test, developed in collaboration with Ellume, is easy to use and provides accurate and objective results in 2 to 15 minutes. Each Digital eHub device, with capacity for up to 8 eSticks, can simultaneously run […]
Read More
Alaska Airlines Partners with AZOVA to Provide Ellume COVID-19 Home Tests & Video Observation for Safe, Healthy Travel

Alaska Airlines Partners with AZOVA to Provide Ellume COVID-19 Home Tests & Video Observation for Safe, Healthy Travel

AZOVA and Ellume provide travelers with a highly accurate result and a secure, shareable digital record of testing and vaccination status via smartphone. ALPINE, UT and FREDERICK, MD – July 1, 2021 AZOVA Inc., creator of the world’s most comprehensive digital health network for COVID-19 testing and vaccination management, and Ellume, the company to bring […]
Read More
New rapid COVID testing options coming to Delta; Purchase and pack for smooth U.S. re-entry

New rapid COVID testing options coming to Delta; Purchase and pack for smooth U.S. re-entry

In partnership with AZOVA, now available Ellume COVID-19 Home Tests are single-packaged and offer highly accurate results in minutes. Delta offering new in-home testing options for purchase that provide results in minutes CDC-accepted tests give customers peace of mind as international travel reopens Delta customers now have more ways to meet COVID-19 test requirements introduced […]
Read More
Ellume establishes flagship U.S. manufacturing facility in Maryland

Ellume establishes flagship U.S. manufacturing facility in Maryland

Industry veterans Jeff Boyle, PhD and Dan Mallon will lead Ellume’s U.S. team to support the company’s rapid growth. Ellume establishes state-of-the-art diagnostic manufacturing facility in Frederick, Maryland, which is on track to begin limited operation in second half 2021; The facility was funded by a $231.8 million agreement with the U.S. Department of Defense […]
Read More
Over-the-counter COVID-19 testing now available at CVS Pharmacy

Over-the-counter COVID-19 testing now available at CVS Pharmacy

Retailer expands access to convenient, at-home testing options with new-to-market, home tests available in stores and online. WOONSOCKET, R.I., Monday, April 19, 2021 — CVS Pharmacy, the retail division of CVS Health (NYSE: CVS), today announced the availability of three over-the-counter COVID-19 testing options in stores and online. The tests include the Ellume COVID-19 Home Test, […]
Read More
Ellume and Cambridge Consultants Collaborate on Core Technology Behind Ellume’s Rapid Antigen COVID-19 Test

Ellume and Cambridge Consultants Collaborate on Core Technology Behind Ellume’s Rapid Antigen COVID-19 Test

Cambridge Consultants developed the ground-breaking optics technology powering Ellume’s FDA authorized COVID-19 Home Test CAMBRIDGE, United Kingdom and BRISBANE, Australia, March 10, 2021 Today, digital diagnostics company Ellume highlights the revolutionary technology created in partnership with global product development and technology consultancy firm, Cambridge Consultants, part of the Capgemini Group. Together, the two companies have […]
Read More
Ellume Announces $231.8 Million Agreement with the U.S. Government

Ellume Announces $231.8 Million Agreement with the U.S. Government

The contract includes the delivery of 8.5 million Ellume COVID-19 Home Tests to support the U.S. Government’s pandemic response The investment will support the establishment of Ellume’s first U.S. manufacturing facility, increasing Ellume’s global production capacity by 500,000+ tests per day once completed; The investment extends Ellume’s engagement with the U.S. government following the NIH […]
Read More
FDA authorizes Ellume COVID-19 Home Test as First Over-the-Counter Fully At-Home Diagnostic Test

FDA authorizes Ellume COVID-19 Home Test as First Over-the-Counter Fully At-Home Diagnostic Test

Proven performance in adults and children, with and without symptoms Highlights FDA grants Emergency Use Authorization for Ellume COVID-19 Home Test for non-prescription home use in symptomatic and asymptomatic individuals The test demonstrated 96% accuracy in a multi-site US clinical study of both adults and children 2 years and above Ellume is ramping up manufacture, […]
Read More
Ellume’s COVID-19 Home Test shows 96% accuracy in multi-site US clinical study

Ellume’s COVID-19 Home Test shows 96% accuracy in multi-site US clinical study

Highlights Ellume submits Emergency Use Authorization to the U.S. Food and Drug Administration for the Ellume COVID-19 home test Clinical study demonstrated overall sensitivity of 95% and specificity of 97% Clinically validated for use in symptomatic and asymptomatic users ages 2 years and above Independently run, simulated home-use clinical study of 198 subjects Ellume is […]
Read More
Ellume awarded US$30M from US National Institutes of Health RADx initiative to accelerate development of rapid COVID-19 diagnostics

Ellume awarded US$30M from US National Institutes of Health RADx initiative to accelerate development of rapid COVID-19 diagnostics

Brisbane, Australia — 7 October 2020 Ellume, a leader in rapid digital diagnostics, today announced it was successfully awarded US$30million from the U.S. National Institutes of Health (NIH) Rapid Acceleration of Diagnostics (RADx) initiative to accelerate the clinical testing and manufacturing scale-up of the company’s COVID-19 antigen tests. Ellume’s core fluorescent immunoassay platform has been […]
Read More
Page 1 of 212
Recent Posts
  • Ellume founder Dr Parsons on COVID testing, Omicron
  • Ellume named Popular Science Best of What’s New 2021
  • Ellume wins AFR BOSS Most Innovative Company Award
  • QIAGEN receives U.S. FDA emergency use authorization for rapid portable SARS-CoV-2 antigen test
  • Push to allow at-home COVID tests in Australia
Archives
Categories
Business
Scroll
ellume logo white
Menu

Home
About Us
COVID-19 Response
Consumer Products
Professional Products
Global Public Health Solutions
Our Tech
News

Quick Links

Contact Us
Terms of Use
Privacy Policy
Whistleblower Policy

Some products pending regulatory clearance and not available for sale. © Ellume Limited 2022
ABN 13 141 767 660